Skip to content

Relationship Between Muscle Mass and Muscle Relaxation Time

Relationship Between Muscle Mass Measured by Bioelectrical Impedance Analysis and Muscle Relaxation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02617433
Enrollment
42
Registered
2015-12-01
Start date
2015-12-31
Completion date
2016-05-31
Last updated
2016-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia

Brief summary

Rocuronium block neuromuscular transmission at the neuromuscular junction, causing paralysis of the affected skeletal muscles. There have been several studies reported positive relationship between muscle mass and amount of neuromuscular junction. The purpose of this study is to find relationship between muscle mass and muscle relaxation time.

Detailed description

Rocuronium block neuromuscular transmission at the neuromuscular junction, causing paralysis of the affected skeletal muscles. There have been several studies reported positive relationship between muscle mass and amount of neuromuscular junction. Until now, dose of rocuronium has been judged by patient's weight and height. However, height and weight do not represent exact muscle mass. The purpose of this study is to find relationship between muscle mass and muscle relaxation time. Measurement of muscle mass will be obtained using bioelectrical impedence analysis.

Interventions

DEVICEInbody

Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours. After measurement, patient is induced anesthesia. Rocuronium dose is 12mg for male, and 9mg for female.

Sponsors

Go Eun Bae
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
19 Years to 64 Years
Healthy volunteers
Yes

Inclusion criteria

* All patient who undergo general anesthesia. * Male; weight 70-75kg , height 170-175cm * Female; weight 53-58kg , height 158-163cm

Exclusion criteria

* Liver and kidney disease * Any types of muscle disorder. * Metal materials or pacemaker in body

Design outcomes

Primary

MeasureTime frameDescription
ratio of result of first stimulus(T1) to result of supramaximal stimulation(T0)two hoursT1 and T0 is obtained by train of four which is commonly used neuromuscular monitoring device.

Secondary

MeasureTime frameDescription
completely suppression time of result of first stimulus(T1).ten minutesT1 is obtained by train of four which is commonly used neuromuscular monitoring device.

Other

MeasureTime frameDescription
Time until reoccurrence of response of first stimulus(T1).two hoursT1 is obtained by train of four which is commonly used neuromuscular monitoring device.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026